CD4 T cells and toxicity from immune checkpoint blockade

T cell dynamism and immune-related adverse events

(2023) Douglas B. Johnson et al.   CANCER CELL

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

(2023) Nicolas Gonzalo Nuñez et al.   Med

Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent

(2022) Bruna Pellini et al.   JOURNAL OF CLINICAL ONCOLOGY

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

(2022) Alexander X. Lozano et al.   NATURE MEDICINE

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

(2022) Jessica P Harris et al.   ONCOLOGIST

CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma

(2022) Kenichi Nishimura et al.   Journal of Personalized Medicine

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

(2022) Léo Plaçais et al.   ANNALS OF THE RHEUMATIC DISEASES

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

(2022) Qing Wu et al.   Journal of Hematology & Oncology

Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines

(2022) Robin Reschke et al.   Cancer Immunology Research

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis

(2022) Amelie Franken et al.   Journal for ImmunoTherapy of Cancer

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

(2022) Dimitrios C. Ziogas et al.   CANCER TREATMENT REVIEWS

Non-viral precision T cell receptor replacement for personalized cell therapy

(2022) Susan P. Foy et al.   NATURE

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors

(2022) Shoiab Bukhari et al.   Cell Reports Medicine

Understanding and treating the inflammatory adverse events of cancer immunotherapy

(2021) Michael Dougan et al.   CELL

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

(2021) Cathrin LC. Gudd et al.   JOURNAL OF HEPATOLOGY

Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis

(2021) Ben J. E. Raveney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

(2021) Riyao Yang et al.   Nature Communications

Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis

(2021) James A. Hutchinson et al.   Nature Communications

CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer

(2021) Paola Marie Marcovecchio et al.   Journal for ImmunoTherapy of Cancer

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice

(2021) Yoshinori Yasuda et al.   Science Translational Medicine

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA

(2021) Mark Kalinich et al.   Journal for ImmunoTherapy of Cancer

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy

(2021) Robin Reschke et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

(2021) Miles C. Andrews et al.   NATURE MEDICINE

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

(2021) Paul Nathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

(2021) Golnaz Morad et al.   CELL

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease

(2021) Everett J. Moding et al.   Cancer Discovery

812 Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells

(2021) Xiaopeng Sun et al.   Journal for ImmunoTherapy of Cancer

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors

(2020) Chiaki Kurimoto et al.   CANCER SCIENCE

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

(2020) Matthew D. Hellmann et al.   CLINICAL CANCER RESEARCH

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

(2020) Xiaoxiang Zhou et al.   BMC Medicine

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

(2020) Adrienne M. Luoma et al.   CELL

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

T-cell repertoire analysis and metrics of diversity and clonality

(2020) Johanna Chiffelle et al.   CURRENT OPINION IN BIOTECHNOLOGY

Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma

(2020) Amy K. Bieber et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients

(2020) Si-Qi Tang et al.   Cancer Research and Treatment

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

(2019) Alessio Cortellini et al.   ONCOLOGIST

Liquid biopsy and minimal residual disease — latest advances and implications for cure

(2019) Klaus Pantel et al.   Nature Reviews Clinical Oncology

Humanized mouse models of immunological diseases and precision medicine

(2019) Leonard D. Shultz et al.   MAMMALIAN GENOME

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

(2019) O Hamid et al.   ANNALS OF ONCOLOGY

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

(2019) V. Ellen Maher et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)

(2019) Re-I Chin et al.   Molecular Diagnosis & Therapy

Determining cell type abundance and expression from bulk tissues with digital cytometry

(2019) Aaron M. Newman et al.   NATURE BIOTECHNOLOGY

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors

(2019) Alberto Pavan et al.   ONCOLOGIST

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

(2019) Douglas B. Johnson et al.   NATURE MEDICINE

T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

(2019) Stacey L. Doran et al.   JOURNAL OF CLINICAL ONCOLOGY

Contraindications to immunotherapy: a global approach

(2019) C. Pitsios et al.   Clinical and Translational Allergy

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes

(2019) Aanika Balaji et al.   Journal of Oncology Practice

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

(2019) Koji Yoshino et al.   BMC CANCER

Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease

(2019) Nathan P. Palmer et al.   PLoS One

Dormant pathogenic CD4+ T cells are prevalent in the peripheral repertoire of healthy mice

(2019) Anna Cebula et al.   Nature Communications

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

(2019) Hiroshi Kagamu et al.   Cancer Immunology Research

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

(2019) Puyuan Xing et al.   Journal for ImmunoTherapy of Cancer

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management

(2018) Adriana T. Lopez et al.   ONCOLOGIST

A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer

(2018) Hatem Soliman et al.   Oncotarget

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

(2018) Julie R. Brahmer et al.   Journal of Oncology Practice

Checkpoint inhibitor colitis

(2018) Spyros I. Siakavellas et al.   CURRENT OPINION IN GASTROENTEROLOGY

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

(2018) Su Y. Lim et al.   CLINICAL CANCER RESEARCH

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

(2017) Yong-Chen Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity

(2017) Ryota Tanaka et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

A functional genomics predictive network model identifies regulators of inflammatory bowel disease

(2017) Lauren A Peters et al.   NATURE GENETICS

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer

(2017) Emma Nolan et al.   Science Translational Medicine

Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA

(2017) Yuan Tian et al.   Nature Communications

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

(2017) Aadel A. Chaudhuri et al.   Cancer Discovery

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression

(2017) Liesbet M. Peeters et al.   Frontiers in Immunology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies

(2016) Arantza Azpilikueta et al.   Journal of Thoracic Oncology

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and risk stratification in patients with anti-RNP autoimmunity

(2015) M F Carpintero et al.   LUPUS

MiXCR: software for comprehensive adaptive immunity profiling

(2015) Dmitriy A Bolotin et al.   NATURE METHODS

Targeting GM-CSF in inflammatory diseases

(2015) Ian P. Wicks et al.   Nature Reviews Rheumatology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression

(2015) T. Hung et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

(2014) T. Chodon et al.   CLINICAL CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent

(2014) Linda J. Bendall et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY

Diversity and clonal selection in the human T-cell repertoire

(2014) Q. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overview of clinical flow cytometry data analysis: recent advances and future challenges

(2013) Carlos E. Pedreira et al.   TRENDS IN BIOTECHNOLOGY

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

(2011) M J M Gooden et al.   BRITISH JOURNAL OF CANCER

Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays

(2009) Wilco de Jager et al.   BMC IMMUNOLOGY

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine